Healthspan Economy

ClinicalTrials.gov · NCT04994561 · Withdrawn

VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements

Registry record

NCT04994561 on ClinicalTrials.gov. The registry's last update to this record was 7 June 2022.

Date checked: . This is the day the Atlas read the registry record; the registry may have changed since.

Verification record

5 checked · 0 company says · 0 reported · 0 not found · 0 not yet checked

  • Title as registered VIAging Deceleration Trial Using Metformin, Dasatinib, Rapamycin and Nutritional Supplements Checked Source clinicaltrials.gov Brief title as registered. Checked
  • Sponsor Vitality in Aging Research Group, Inc. Checked Source clinicaltrials.gov Lead sponsor as registered. Checked
  • Intervention Study Drugs and Nutritional Supplements Checked Source clinicaltrials.gov Intervention names as registered. Checked
  • Primary outcome as registered Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0 | Visceral adipose tissue fat tissue (volume (in^3)) physiological parameter value measured by DEXA scan | Systolic blood pressure physiological parameter value measured with a blood pressure cuff | Senescent cell-cycle arrest physiological parameter value measured by MMP-9 laboratory test (and 2 more registered) Checked Source clinicaltrials.gov Primary outcome measure(s) as registered. Checked
  • Status Withdrawn Checked Source clinicaltrials.gov Overall status as registered; registry last update 2022-06-07. Checked

Check history: NCT04994561 was last read on the registry on November 14, 2026. No earlier checks are recorded. How records are checked.

Corrections: none recorded for this trial. To ask for one, write to [email protected] with the registry number; every correction is checked against the registry record before the record changes.

As registered

  • Sponsor: Vitality in Aging Research Group, Inc.
  • Phase: Phase 1
  • Status: Withdrawn
  • Intervention: Study Drugs and Nutritional Supplements
  • Primary outcome: Incidence of treatment-emergent adverse events as assessed by CTCAE v5.0 | Visceral adipose tissue fat tissue (volume (in^3)) physiological parameter value measured by DEXA scan | Systolic blood pressure physiological parameter value measured with a blood pressure cuff | Senescent cell-cycle arrest physiological parameter value measured by MMP-9 laboratory test (and 2 more registered)
  • Countries: Not stated
  • Start: June 2022
  • Completion (estimated): December 2023

Results

No results were posted on the registry on the date checked. The Atlas does not summarize findings.

Related modality

A trial being registered is not evidence that the intervention works.